Patients who received, are currently receiving, or are going to receive PAXLOVID according to locally approved label.
Patients (or a legally acceptable representative) who are willing to provide written informed consent/assent prior to study enrollment.
You may not be if
Patients with contraindication according to locally approved label of PAXLOVID.
Patients who are going to receive any investigational medicine during the observation period.
Clareo Health | A Study on Paxlovid Once in the Market, to Observe Its Safety and Effectiveness in Patients Who Have a High Chance of Getting Severe COVID-19
